COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY

Mullokulov J.J., Akhmedov Kh.S.

Вестник Ассоциации пульмонологов Центральной Азии · 2025-yil

Annotatsiya

Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF-α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce.

Maqola ma’lumotlari
MualliflarMullokulov J.J., Akhmedov Kh.S.
JurnalВестник Ассоциации пульмонологов Центральной Азии
Nashr sanasi2025-10-18
Jild13
Son8
Betlar21-26
TilRus

Kalit so‘zlar

reactive arthritis, baricitinib, adalimumab, DAREA, BASDAI.

Ilmiy soha

Вестник Ассоциации пульмонологов Центральной Азии jurnalidan boshqa maqolalar

Вестник Ассоциации пульмонологов Центральной Азии — barcha maqolalar